Breast Imaging

What Is the Initial Imaging for a Clinically Node-Negative Axilla Before Neoadjuvant Therapy?

·
What Is the Initial Imaging for a Clinically Node-Negative Axilla Before Neoadjuvant Therapy?

A 45-year-old patient with a new diagnosis of triple-negative breast cancer is in your clinic to discuss the treatment plan. The medical oncologist recommends neoadjuvant chemotherapy (NAC) to shrink the tumor before surgery. On physical examination, you find no palpable, firm, or fixed lymph nodes in the axilla; the patient is clinically node-negative (cN0). The multidisciplinary team needs to accurately stage the axilla before systemic therapy begins, as the presence of even occult nodal metastases will significantly alter the post-chemotherapy surgical plan. You need to order the correct initial imaging study to evaluate the axillary lymph nodes. This article details the clinical workflow for this specific scenario, explaining why the American College of Radiology (ACR) designates axillary ultrasound as Usually Appropriate.

Who Fits This Clinical Scenario?

This guidance applies to any adult patient—female, male, transfeminine, or transmasculine—with a confirmed diagnosis of breast cancer who is scheduled to receive neoadjuvant systemic therapy and has a clinically negative axilla on physical exam. The key inclusion criteria are:

  • Known diagnosis of breast cancer.
  • Plan for neoadjuvant chemotherapy or other systemic therapy.
  • No suspicious lymph nodes palpable on a thorough physical examination of the axilla.
  • This is the initial imaging evaluation of the axilla in the pre-treatment setting.

It is crucial to distinguish this situation from closely related but distinct clinical presentations that require a different approach. This workflow does not apply if:

  • The patient is clinically node-positive. If suspicious lymph nodes are palpable on exam, the patient should proceed directly to ultrasound-guided tissue sampling (fine-needle aspiration or core biopsy) to confirm metastatic disease, not just an initial imaging survey.
  • Neoadjuvant therapy is not planned. Patients proceeding directly to surgery typically undergo axillary staging via sentinel lymph node biopsy in the operating room.
  • The patient has already undergone axillary imaging. This guidance is for the first-line, initial evaluation, not for follow-up or problem-solving after a prior study has been performed.

What Diagnoses Are You Working Up in This Scenario?

The primary goal of imaging in this setting is to identify occult axillary nodal metastases that are not detectable by physical exam. Up to 40% of patients with a clinically negative axilla may have positive nodes upon pathologic review. Identifying these patients before NAC is critical for accurate staging and appropriate surgical planning after therapy is complete. The differential considerations for axillary lymph node findings include:

Metastatic Lymph Node
This is the principal diagnosis to identify or exclude. Malignant cells from the primary breast tumor can travel through lymphatic channels and establish a secondary tumor deposit in an axillary lymph node. Imaging features suggestive of metastasis include cortical thickening (often asymmetric or focal), a rounded (non-oval) shape, and partial or complete effacement of the normal fatty hilum. Confirming this finding up-front changes the patient’s stage and ensures the involved node can be marked for later surgical removal.

Reactive (Benign) Lymphadenopathy
Lymph nodes can become enlarged and prominent for reasons other than cancer, such as inflammation or infection. This is a common finding and a key mimic of malignancy. Reactive nodes typically maintain their oval shape and preserve the central fatty hilum, though they may show diffuse, symmetric cortical thickening. Distinguishing reactive changes from early metastatic involvement is a primary task of the interpreting radiologist.

Normal Lymph Nodes
The ideal finding is an axilla containing only normal-appearing lymph nodes. These are typically small, oval-shaped, and have a distinct, bright-white fatty hilum on ultrasound with a thin, uniform cortex. A definitively negative axillary ultrasound allows the patient to proceed with NAC, staged as cN0.

Why Is Axillary Ultrasound the Recommended Initial Study?

The ACR Appropriateness Criteria rate US axilla as Usually Appropriate for this scenario, making it the clear first-choice imaging modality. This recommendation is based on its high sensitivity for detecting suspicious nodal features, lack of ionizing radiation, and ability to seamlessly guide subsequent biopsy if needed.

Axillary ultrasound provides high-resolution detail of lymph node morphology. It is highly effective at identifying features of malignancy, such as cortical thickening, a rounded shape, and loss of the fatty hilum. Its performance allows clinicians to confidently identify patients with occult nodal disease who were missed on physical exam. Furthermore, as a non-invasive test with no radiation exposure (0 mSv), it is exceptionally safe for all patients.

Conversely, other imaging modalities are rated Usually Not Appropriate as the initial step:

  • US-guided fine needle aspiration (FNA) or core biopsy: These are not imaging studies but rather diagnostic procedures. They are the logical next step after a suspicious node is identified on ultrasound, not the initial screening tool. Ordering a biopsy without a pre-identified imaging target is inappropriate.
  • MRI breast without and with IV contrast: While excellent for evaluating the primary breast tumor, breast MRI has lower spatial resolution in the axilla compared to a dedicated ultrasound. It is less sensitive and specific for subtle nodal abnormalities and is not the primary tool for axillary staging.
  • FDG-PET/CT skull base to mid-thigh: This is a powerful tool for detecting distant metastatic disease but is overkill for initial axillary staging in a cN0 patient. It involves a significant radiation dose (☢☢☢☢ 10-30 mSv) and is not cost-effective for this indication. It is typically reserved for patients with locally advanced disease (e.g., large tumors or clinically positive nodes) or inflammatory breast cancer.

The rationale is clear: start with the safest, most targeted, and most effective test. Axillary ultrasound directly answers the clinical question—are there morphologically suspicious nodes?—without the radiation, cost, or lower specificity of alternative tests.

What’s Next After Axillary Ultrasound? Downstream Workflow

The results of the axillary ultrasound will direct the subsequent steps in the patient’s management plan. The workflow branches into three main pathways:

If the ultrasound is positive (one or more suspicious nodes identified):
The next step is to obtain a tissue diagnosis. An ultrasound-guided biopsy (either FNA or, more commonly, a core needle biopsy) of the most suspicious-appearing lymph node should be performed. If the biopsy confirms metastatic disease, a biopsy clip must be placed into the sampled node. This clip is critical, as it marks the proven-positive node, allowing the surgeon to find and remove it after neoadjuvant therapy, a procedure known as targeted axillary dissection (TAD).

If the ultrasound is negative (all visible nodes appear normal or benign):
The patient is considered to have an imaging-negative axilla and can proceed with neoadjuvant chemotherapy as planned. Their axilla will be surgically staged after completion of NAC, typically with a sentinel lymph node biopsy (SLNB). If the sentinel nodes are negative after treatment, the patient may be able to avoid a full axillary lymph node dissection.

If the ultrasound is indeterminate or equivocal:
In some cases, a node may have features that are not definitively benign or malignant. Given the importance of accurate pre-treatment staging, ambiguity should be resolved with a biopsy. The threshold to recommend a biopsy for an indeterminate node in the pre-NAC setting is low, as confirming or refuting the presence of cancer is critical for subsequent surgical planning.

Pitfalls to Avoid (and When to Get Help)

While axillary ultrasound is a robust tool, several pitfalls can compromise its accuracy. Awareness of these issues can help ensure a correct diagnosis and appropriate patient care.

  • Incomplete Examination: A “quick look” is insufficient. The sonographer must perform a systematic survey of all axillary levels (I, II, and the interpectoral space) to ensure no suspicious nodes are missed.
  • Misinterpreting Reactive Nodes: Symmetrically prominent but otherwise normal-appearing nodes can be mistaken for malignancy, leading to unnecessary biopsies. Close attention to morphology (preserved fatty hilum, oval shape) is key.
  • Biopsying the Wrong Node: If multiple abnormal nodes are present, the one with the most malignant features (e.g., the most rounded, most cortically thickened) must be targeted for biopsy to maximize diagnostic yield.
  • Failing to Clip a Positive Node: If a biopsy-proven metastatic node is not marked with a clip, it may become impossible to identify after a good response to chemotherapy, preventing the surgeon from performing a targeted axillary dissection.

If the ultrasound findings are discordant with a high-risk primary tumor or a subtle clinical finding, escalation to a multidisciplinary tumor board discussion is the most appropriate next step before proceeding.

Related ACR Topics and Tools

For a comprehensive overview of all clinical variants related to imaging before, during, and after neoadjuvant therapy, please consult the parent topic article. For additional decision support, the following resources are available:

Frequently Asked Questions

Why not perform a sentinel lymph node biopsy (SLNB) on everyone before starting neoadjuvant chemotherapy?

Performing SLNB before NAC was a common practice in the past. However, it has a key disadvantage: it can disrupt the lymphatic channels, potentially affecting the accuracy of a repeat SLNB if one is needed after chemotherapy. The current standard of care, supported by major clinical trials, is to perform an initial axillary ultrasound with biopsy of suspicious nodes. This approach accurately stages the axilla non-surgically and preserves the axillary lymphatics for a definitive SLNB after NAC is complete.

Does this guidance apply to patients with inflammatory breast cancer (IBC)?

No. Inflammatory breast cancer is considered a locally advanced disease (T4d) by definition, and patients are presumed to have nodal involvement. The standard workup for IBC is more extensive and typically includes FDG-PET/CT for comprehensive staging of nodal, regional, and distant disease, not just a screening axillary ultrasound.

What if the primary breast tumor is not visible on ultrasound? Can I still rely on an axillary ultrasound?

Yes. The ability to visualize the primary tumor does not impact the effectiveness of a dedicated axillary ultrasound. The evaluation of the axillary lymph nodes is a separate and distinct examination. Even if the primary cancer is only seen on mammography or MRI (e.g., calcifications or non-mass enhancement), axillary ultrasound remains the ‘Usually Appropriate’ first step for evaluating the nodes.

How does this workflow change for male or transgender patients with breast cancer?

The clinical workflow for axillary staging before neoadjuvant therapy is identical regardless of the patient’s sex or gender identity. The principles of lymphatic drainage and the imaging characteristics of metastatic lymph nodes are the same. Axillary ultrasound is the recommended initial imaging test for all adult patients in this scenario.

If the axillary ultrasound is negative, is there any role for MRI to ‘double-check’ the nodes?

No, this is rated as ‘Usually Not Appropriate’ by the ACR. A dedicated, high-quality axillary ultrasound is considered the most sensitive test for nodal morphology. Adding a breast MRI solely to re-evaluate a normal-appearing axilla adds cost and the potential for false-positive findings without a proven benefit in diagnostic accuracy for the nodes.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026